WIA-ALZHEIMERS: Integrated Treatment Standard

A unified standard for Alzheimer's disease treatment through NAD+ homeostasis recovery. Integrating distributed research approaches to restore cognitive function for all patients worldwide.

🎮 Try Simulator 📚 Read Ebook 📋 View Specification

Unifying Principle

NAD+ Homeostasis = Metabolic Balance = Alzheimer's Reversal

NAD+ Homeostasis Index = f(NAD+ Level, NADH/NAD+ Ratio, Sirtuin Activity, PARP Activity)

Complete neurological recovery achieved in mouse models through metabolic balance restoration (Cell Reports Medicine, 2025)

Four-Phase Implementation

Data Format

NAD+ homeostasis index, Alzheimer's pathology profiles, cognitive assessment scores, and biomarker tracking schemas.

✅ Complete

API Interface

RESTful and GraphQL APIs for assessment, intervention recommendation, treatment tracking, and biomarker integration.

✅ Complete

Protocol

Measurement protocols for NAD+ metabolism, cognitive assessments, and intervention protocols including NR/NMN supplementation.

✅ Complete

Integration

FHIR R5 compatibility, EHR integration, laboratory connectivity, wearable data aggregation, and 4-level certification.

✅ Complete

By The Numbers

55M+ People with Dementia Worldwide

45% NAD+ Decline in Advanced AD

100% Cognitive Recovery in Mouse Models

99 Language Support

Treatment Pillars

🔋

NAD+ Precursors (NR/NMN)

🧬

Mitochondrial Function

💉

Anti-Amyloid Therapy

🧪

Tau Reduction

🛡️

BBB Protection

🧠

Synaptic Plasticity

🔥

Neuroinflammation Control

📊

Biomarker Monitoring

Key Research (2024-2025)

Complete Neurological Recovery (Cell Reports Medicine, 2025)

P7C3-A20 restores NAD+ homeostasis in advanced AD mice, reversing tau phosphorylation, BBB damage, and cognitive deficits.

NMN Mitochondrial UPR Improvement (Cell Death Disease, 2024)

NMN activates ATF4-dependent mitochondrial unfolded protein response, protecting hippocampal synapses and reducing neuronal loss.

NR Clinical Trial (Alzheimer's & Dementia, 2025)

Double-blind RCT of nicotinamide riboside 1g/day for 8 weeks in subjects with subjective cognitive decline or MCI.

Lecanemab & Donanemab Efficacy (eNeuro, 2024)

25-30% slowing of disease progression over 18 months with anti-amyloid antibodies targeting protofibrils and pyroglutamate-modified plaques.